Non-Small Cell Lung Carcinoma – Page 4

FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website

10 months ago talkbio0Tagged Cancer Therapeutic Procedure, Claims, Effectiveness, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, non-small-cell lung cancer, squibb, United States Food and Drug Administration

Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment

Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials

10 months ago talkbio0Tagged Carcinoma of anal margin, Incyte, Inhibitor, Non-Small Cell Lung Carcinoma, PDCD1 gene, Phase 3, Zynyz

Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer

FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC

10 months ago talkbio0Tagged AdComm, AstraZeneca, Imfinzi, Immune Checkpoint Inhibitors, Immunologic Adjuvants, Neoadjuvant Chemotherapy, Non-Small Cell Lung Carcinoma, Overtreatment, perioperative, Single Agent Therapy, United States Food and Drug Administration

AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

11 months ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)

FDA Rejects Merck-Daiichi Sankyo’s Lung Cancer Drug, Approves New Treatments for COPD and Lymphoma

12 months ago talkbio0Tagged Chronic Obstructive Airway Disease, Daiichi, Deruxtecan, ensifentrine, Lymphoma, Merck, Non-Small Cell Lung Carcinoma, patritumab, Sankyo, United States Food and Drug Administration

FDA, Merck, Daiichi Sankyo, NSCLC, COPD, Lymphoma, Patritumab Deruxtecan, Ensifentrine, Epkinly

RYBREVANT: A Breakthrough in Lung Cancer Treatment

1 year ago talkbio0Tagged Epidermal Growth Factor Receptor, Infusion-Related Reaction, intravenous administration, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous administration, Survival Rate

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)

Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO

1 year ago talkbio0Tagged Akeso, ASCO, Ivonescimab, Keytruda, Malignant Neoplasms, Non-Small Cell Lung Carcinoma, PDCD1 gene, summit, Vascular Endothelial Growth Factor A

Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

1 year ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

Bristol Myers Squibb’s KRAZATI Confirmed Effective in Pivotal Phase 3 KRYSTAL-12 Trial Following Accelerated Approval

1 year ago talkbio0Tagged Accelerated Approval, adagrasib, Approved, bristol-myers, Clinical Benefit, Confirmatory Trial, Continuous, June 21/ 2024, KRASG12C mutation, KRAZATI, KRYSTAL-12, Locally, Metastatic to, Non-Small Cell Lung Carcinoma, ORR, Overall response rate, PDUFA, Primary Endpoint, Progression-Free Survival, squibb, United States Food and Drug Administration, Verification of Theories

Bristol Myers Squibb, KRAZATI (adagrasib), Pivotal Phase 3 trial, KRYSTAL-12 study, Primary endpoint met, Progression-free survival (PFS), Overall response rate (ORR), Confirmatory trial, Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, KRASG12C mutation, Accelerated approval, Continued approval contingent on clinical benefit verification, FDA assigned PDUFA goal date of June 21/ 2024